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Abstract
Substantial changes in large parts of the developing world have materialised in the last three decades. These are
extremely diverse countries with respect to culture, societal values and political arrangements, but sharing one
feature - prevalent poverty and limited resources to protect the health of individuals. The control of emerging
chronic diseases in low-resource countries is a formidable challenge. For this reason any intervention should be
kept logistically simple and incorporated into a general plan aiming at building gradually the infrastructure that is
necessary to bring care to the population at large. The present contribution summarizes some of the priorities in
cancer prevention in developing countries and the underlying evidence base, and addresses some of the
challenges.
Background
Many countries in sub-Saharan Africa still struggle with
endemic tuberculosis, malaria, AIDS, nutritional defi-
ciencies and perinatal conditions that cause high rates
of premature death and permanent disability, a disease
burden at least one order of magnitude greater than
cancer. But even where substantial economic develop-
ment has taken place, as in Thailand, Malaysia, China,
India or Brazil, it has failed to benefit society at large;
rather, new health threats are on the rise with limited
control of the long-term burden of prevalent diseases.
Moreover, the lack of comprehensive planning of health
systems has led to wider inequalities in access to health
care.
Cancer control encompasses a package of diverse
interventions [1] aiming at reducing morbidity and mor-
tality from the disease, with wide variations in costs and
potential impact. Under serious budgetary constrains
and competition with the demands of other diseases,
cancer control programmes need to make wise choices
to maximise the efficacy of their investments.
Choices should be driven primarily by the quantifica-
tion of the problem combined with the feasibility and
cost of different interventions. Means to monitor the
occurrence of cancer in developing countries are still
very limited, therefore planning relies largely on esti-
mates. Based on the comprehensive GLOBOCAN2008
[2] dataset, in developing countries as a whole cancers
of the lung, stomach, breast, liver, colorectum and cervix
are the most common sites in this order, each is at least
twice more frequent than the majority of any other can-
c e rt y p e( F i g u r e1 ) ;t h e ya r eam i xo fm a l i g n a n c i e s
linked to infections and poverty (stomach, liver and cer-
vix) and westernization of life styles (lung, breast and
colorectum). The Figure 1 shows for comparison the
ranking in affluent regions where the four top sites are
lung, breast, colorectum and prostate. In the context of
cancer control it is particularly important to remark
that in both high- (generally rich) and low-risk (gener-
ally less wealthy) countries, such common sites account
for only half of the burden.
Options for prevention
Smoking of commercial cigarettes used to be uncom-
mon in developing countries where tobacco smoking is
a recent aspect of Westernization of life styles. While
interventions to reduce the habit in rich countries is
now showing positive results, the tobacco industry is
pursuing new markets in the developing world [3,4]. Of
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comprehensive programmes to prevent tobacco smoking
are the most cost-effective: the impact on future chronic
d i s e a s eb u r d e ni st h el a r g e s ta c h i e v a b l eb yp r e v e n t i n g
one single factor, against measures that are inexpensive
to governments such as banning smoking in public
places and impose high taxes on the product. Tobacco
prevention should be a priority for all countries.
Immunization of infants against hepatitis B virus
(HBV) is probably the second most cost-effective option
in regions where the infection is still endemic. Lorenzo
Tomatis at the International Agency for Research on
Cancer saw the potential of such public health measure
in the early eighties when he promoted the establish-
ment of The Gambia Hepatitis Intervention Study
(GHIS). The main objective of the study was to prove
the feasibility of such interventions and quantify the effi-
cacy of immunization in preventing chronic liver dis-
eases and hepatocellular cancer in an African country.
Several more years of observation are needed to
measure the full impact of the intervention; but high
coverage and reduced incidence of chronic hepatitis
have been achieved [5] promising success also with
respect to the malignant disease. Sadly, immunization
coverage remains low in the regions that would benefit
most from this public health measure (Figure 2).
One of the most celebrated successes of cancer
research is the recognition that virtually all cervix can-
cers are caused by certain types of the Human Papil-
loma Virus (HPV) with types 16 and 18 accounting for
about 80% of the burden [6]. The finding led to the
development and testing of vaccines that are now
approved in many countries. The logistics of high cover-
age HPV immunization programmes is more complex
than that of vaccination of infants since they target ado-
lescents before they become sexually active. Inherent
difficulties are amplified in developing countries where
access to preventive medical services is limited in parti-
cular for girls. Even under the ideal (and unrealistic)
hypothesis that all new generations of girls will be
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Figure 1 Cancer incidence 2008, males and females. Estimated numbers of new cases per year by level of economical development [2].
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continue to be threatened by cervix cancer for decades.
A realistic view must recognise that large strata of
w o m e ni nd e v e l o p i n gc o u n t r i e sw i l lc o n t i n u et ob e
exposed to the infection and will develop the disease.
Prevention of invasive cancer by early detection and
timely treatment will remain therefore an important
component of cancer control policies.
Compared with classical cytology-based screening, the
HPV technology offers a valid and possibly more cost-
effective strategy in secondary prevention of cervix can-
cer in low-resource settings, because the sensitivity and
specificity of available HPV tests in exfoliated cells are
much more reproducible than those of cytology which
strongly depends on human expertise and skill [7]. In
fact, to maintain high quality standards of screening by
cytology in developing countries has proved difficult,
costly, and too often ineffective.
In a large randomised trial in Kerala, India, Sankara-
nayan and colleagues [8] assessed the efficacy of a single
examination by three screening modalities —HPV test-
ing by Hybrid Capture II for 16 high-risk types, cytology
and visual inspection with acetic acid (VIA) — in redu-
cing mortality from cervix cancer compared with back-
ground rates achieved by usual care. The intervention
was designed to maximise compliance of positive
women with diagnostic follow-up and treatment, given
local living conditions and infrastructure. Colposcopy
and biopsy of all suspicious lesions were performed dur-
ing the screening visit; small lesions were treated by
cryotherapy or loop electrosurgical excision in primary
health units. Eight years after a single screen examina-
tion, mortality from cervix cancer was halved in those
HPV-tested. Smaller reductions were found in women
screened by the other two modalities. This project
proves that screening for HPV combined with the see-
and-treat strategy is an effective intervention requiring
limited expenditure.
There is no single strategy to develop cervix cancer
control programmes from scratch. With a careful analy-
sis of the size of the problem, feasibility, costs and
expected outcomes against the background of existing
infrastructure, plans can be gradually built from a mini-
mal level —e.g. one life-time HPV-based screening test
with timely treatment accessible to all women from age
35 years— a n de x p a n d e do nt h em e d i u m -o rl o n g - t e r m
with immunization programmes and repeated screening.
The condition for any intervention to be successful and
cost-effective is to reach high coverage of the target
population; therefore, much attention must be paid to
the logistics of how the services are delivered in order
to ensure access and high compliance.
Other preventive interventions that are the object of
much research and activities in the West focus on nutri-
tional habits and energy balance, clearly an increasing
problem in emerging economies as shown by rising
rates of diabetes [9] . Tackling obesity and excessive
body weight is proving a difficult task in Western coun-
tries; it might be even more difficult in populations
where over-nutrition coexists with malnutrition. Doc-
tors, health care operators and teachers are in the best
position to advise and counsel people; they should be
made aware of their responsibility and be trained to
monitor, educate and convey targeted messages.
The increased risk of breast cancer in emerging
economies is seen as the direct expression of econom-
ical development; yet, our understanding of the modifi-
able causes of the disease is still very limited leaving
little room for primary prevention beyond avoiding
excessive body weight. Improving access to timely treat-
ment of early palpable tumours is likely to result in a
greater benefit to the population. Etiological research in
populations still at low or intermediate risk for the dis-
ease offer instead powerful opportunities to test hypoth-
eses based on observations made in the high-risk
Western world.
Finally, an area that is often overlooked among pre-
ventive actions in low-resource countries is the uncon-
trolled use of carcinogens in industrial processes and
economical activities, often imported from technologi-
cally advanced economies where regulations impose
uses that are safe for workers and the environment, but
less profitable. Any attempt to estimate the magnitude
of the current and future disease burden due to poten-
tial carcinogens newly introduced under uncontrolled
conditions would be highly controversial as lack of regu-
lations implies also lack of monitoring of the amount,
usage and disposal of hazardous substances. Nonethe-
less, whatever the size of the problem, ethical principles
impose the inclusion in any cancer control programme
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Figure 2 Immunization coverage among 1-year-olds (WHO).
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onmental contamination with carcinogens. As a first
step in this direction both rich and poor countries
should be encouraged to sign up to the Rotterdam Con-
vention whose objectives are to promote shared respon-
sibility in the international trade of hazardous chemicals
and to contribute to their sound use [10]. Bodies sub-
scribing to the Convention commit to disseminate infor-
mation on the characteristics and hazards of substances
traded among parties.
Cancer care
In rich countries the combination of early detection and
new treatments that can improve disease outcomes have
contributed to a modest but constant decline in cancer
mortality rates that started in the 1980s [11]. The main
determinant of such success is not the availability of
more effective curative drugs but widespread access to
health care through comprehensive health systems. In
developing countries, poor infrastructure to intervene
timely and to deliver even basic care may jeopardize
well-meaning projects directed to specific diseases or
conditions. Actions directed to specific outcomes, e.g.
making treatment for some childhood malignancies and
early breast cancer available to all cases, should be
selected and included in a cancer control plans only if
they have high potential impact (high rate of success) at
affordable costs. Having this principles in mind, the
development of means to provide pain relief and pallia-
tive care to cancer cases and other terminally ill patients
is a much cost-effective option (in developing countries
two cases in three die from the disease): to reduce the
suffering is a benefit that all human beings value, it does
not require sophisticated technology, and it is for all
cases. Back in the 1980s, having recognised that lack of
access to palliative care in poor countries was a major
public health problem, the WHO established the Cancer
Pain Programme [12]. Twenty years later, palliative care
still struggles to gain priority with policy-makers. Only
recently palliative care and pain relief programmes have
been considered a necessary component of the mini-
mum core services that health systems ought to offer to
citizens [13] .
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